Idiopathic normal-pressure hydrocephalus: the cost-effectiveness of delivering timely and adequate treatment in Germany.
care pathway
cost-effectiveness analysis
neurological disorder
normal pressure hydrocephalus
shunt surgery
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
29
09
2020
accepted:
06
10
2020
pubmed:
13
10
2020
medline:
13
8
2021
entrez:
12
10
2020
Statut:
ppublish
Résumé
Idiopathic normal-pressure hydrocephalus (iNPH) is a progressive, severe brain disorder, which mainly affects people above the age of 65 years. iNPH is characterized by the accumulation of excess cerebrospinal fluid in the brain's ventricles. In most cases, iNPH patients can be effectively treated with shunt surgery, which involves placing a tube into the brain to drain the excess fluid. As part of the European Brain Council-led Value of Treatment project, this study aimed to investigate the cost-effectiveness of delivering timely and adequate iNPH treatment in Germany. The study identified treatment gaps that prevent iNPH patients from receiving adequate and timely treatment. The cost-effectiveness of delivering shunt surgery to iNPH-prevalent patients aged ≥65 years in Germany was calculated using decision-analytical modelling. The model compared two alternatives, current care (shunt surgery in 25% of iNPH cases) and target care (shunt surgery in 90% of iNPH cases), and looked at healthcare costs (diagnosis, shunt intervention and follow-up care) from the public health insurance perspective, as well as effectiveness outcomes in terms of lives saved and quality-adjusted life-years (QALYs) gained. Delivering timely and adequate iNPH treatment proved to be cost-effective. Cost per life saved varied between €27 921 at 5 years and €246 726 at 15 years. Cost-per-QALY estimates varied between €10 202 at 5 years and €35 128 at 15 years. Idiopathic normal-pressure hydrocephalus is a treatable but often not-treated disease, resulting in unnecessary and avoidable disease burden for the healthcare system. Actions required to close this treatment gap are straightforward and their implementation has been modelled with successful outcomes.
Sections du résumé
BACKGROUND AND PURPOSE
Idiopathic normal-pressure hydrocephalus (iNPH) is a progressive, severe brain disorder, which mainly affects people above the age of 65 years. iNPH is characterized by the accumulation of excess cerebrospinal fluid in the brain's ventricles. In most cases, iNPH patients can be effectively treated with shunt surgery, which involves placing a tube into the brain to drain the excess fluid. As part of the European Brain Council-led Value of Treatment project, this study aimed to investigate the cost-effectiveness of delivering timely and adequate iNPH treatment in Germany.
METHODS
The study identified treatment gaps that prevent iNPH patients from receiving adequate and timely treatment. The cost-effectiveness of delivering shunt surgery to iNPH-prevalent patients aged ≥65 years in Germany was calculated using decision-analytical modelling. The model compared two alternatives, current care (shunt surgery in 25% of iNPH cases) and target care (shunt surgery in 90% of iNPH cases), and looked at healthcare costs (diagnosis, shunt intervention and follow-up care) from the public health insurance perspective, as well as effectiveness outcomes in terms of lives saved and quality-adjusted life-years (QALYs) gained.
RESULTS
Delivering timely and adequate iNPH treatment proved to be cost-effective. Cost per life saved varied between €27 921 at 5 years and €246 726 at 15 years. Cost-per-QALY estimates varied between €10 202 at 5 years and €35 128 at 15 years.
CONCLUSIONS
Idiopathic normal-pressure hydrocephalus is a treatable but often not-treated disease, resulting in unnecessary and avoidable disease burden for the healthcare system. Actions required to close this treatment gap are straightforward and their implementation has been modelled with successful outcomes.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
681-690Informations de copyright
© 2020 European Academy of Neurology.
Références
Jaraj D, Rabiei K, Marlow T, Jensen C, Skoog I, Wikkelso C. Prevalence of idiopathic normal-pressure hydrocephalus. Neurology 2014; 82: 1449-1454.
Andersson J, Rosell M, Kockum K, Lilja-Lund O, Söderström L, Laurell K. Prevalence of idiopathic normal pressure hydrocephalus: a prospective, population-based study. PLoS One 2019; 14: 5.
Fisher CM. Hydrocephalus as a cause of disturbances of gait in the elderly. Neurology 1982; 32: 1358.
Relkin N, Marmarou A, Klinge P, Bergsneider M, Black PM. Diagnosing Idiopathic Normal-pressure Hydrocephalus. Neurosurgery 2005; 57: S2-4-S2-16.
Fritsch M, Kehler U, Meier U, eds. Normal Pressure Hydrocephalus. Stuttgart, New York, Dehli, Rio: Thieme Verlag, 2014.
Nassar BR, Lippa CF. Idiopathic normal pressure hydrocephalus. Gerontol Geriatr Med 2016; 2: 2333721416643702.
Petersen J, Hellström P, Wikkelsø C, Lundgren-Nilsson Å. Improvement in social function and health-related quality of life after shunt surgery for idiopathic normal-pressure hydrocephalus. J Neurosurg 2014; 121: 776-784.
Kameda M, Yamada S, Atsuchi M, et al. Cost-effectiveness analysis of shunt surgery for idiopathic normal pressure hydrocephalus based on the SINPHONI and SINPHONI-2 trials. Acta Neurochirurgica 2017; 159: 995-1003.
Unterberg A. The differential diagnosis and treatment of normal-pressure hydrocephalus. Deutsch Ärztebl Int 2012; 109: 15-25.
Tullberg M, Persson J, Petersen J, Hellström P, Wikkelsø C, Lundgren-Nilsson Å. Shunt surgery in idiopathic normal pressure hydrocephalus is cost-effective-a cost utility analysis. Acta Neurochirurgica 2018; 160: 3.
Pfannstiel MA, Rasche C. Service Design and Service Thinking in Healthcare and Hospital Management. Springer, 2019.
Schrijvers G, van Hoorn A, Huiskes N. The care pathway: concepts and theories: an introduction. Int J Integr Care 2012; 12: e192.
Petrou S, Gray A. Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting. BMJ 2011; 11: 342.
Kiefer M, Unterberg A. The differential diagnosis and treatment of normal-pressure hydrocephalus. Dtsch Arztebl Int 2012; 109: 15-26.
Williams MA, Sharkey P, Van Doren D, Thomas G, Rigamonti D. Influence of shunt surgery on healthcare expenditures of elderly fee-for-service Medicare beneficiaries with hydrocephalus. J Neurosurg 2007; 17: 1.
Gölz L, Ruppert F-H, Meier U, Lemcke J. Outcome of modern shunt therapy in patients with idiopathic normal pressure hydrocephalus 6 years postoperatively. J Neurosurg 2014; 121: 771-5.
Jaraj D, Wikkelsø C, Rabiei K, Marlow T, Jensen C, Östling S, Skoog I. Mortality and risk of dementia in normal-pressure hydrocephalus: A population study. Alzheimers Dement 2017; 13: 850-857.
Larsen HI. Comorbidity and vascular risk factors associated with idiopathic normal pressure hydrocephalus: The INPH-CRasH Study. Umeå University Medical Dissertations, 2016.
DRG list in Germany, 2016 11. A lles über Pflegestufe 0, 1, 2 & 3 (Stand: 2016). https://www.jedermann-gruppe.de/pflegestufen-1-2-3/ [Last visited July 2017].
Jedermann Gruppe https://www.jedermann-gruppe.de/, 2016 [Last visited July 2017].
Oliveira LM, Nitrini R, Román GC. Normal-pressure hydrocephalus: a critical review [published correction appears in. Dement Neuropsychol 2019; 13: 361.
Peterson KA, Savulich G, Jackson D, Killikelly C, Pickard JD, Sahakian BJ. The effect of shunt surgery on neuropsychological performance in normal pressure hydrocephalus: a systematic review and meta-analysis. J Neurol 2016; 263: 1669-1677.
McGirt MJ, Woodworth G, Coon AL, Thomas G, Williams MA, Rigamonti D. Diagnosis, treatment, and analysis of long-term outcomes in idiopathic normal-pressure hydrocephalus. Neurosurgery 2005; 57: 699-705.
Coulter A, Collins A. Making shared decision-making a reality. No decision about me, without me. The King's Fund, 2011.
European Brain Council. The value of treatment policy white paper: towards optimizing research and care for brain disorders. Brussels: European Brain Council, 2017. Available at: http://www.braincouncil.eu/wp-content/uploads/2017/06/EBC_white_policy_paper_DEF26072017_Low.pdf